Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 591

Is Medibank Private a bargain?

The Medibank and ahm private health insurance brands serve over 4.2 million customers and play a vital role in funding medical care in Australia. In the most recent financial year, Medibank paid out $6.3 billion in health insurance claims, taking a significant burden off the public healthcare system.

Yet recently, the sector has come under fire from both the government and hospitals accused of making too much profit. In this article, we explore this regulatory tension and why we think Medibank looks an attractive investment opportunity.

Private hospital profits affected by new models of care

There is no doubt the past few years have been challenging for hospitals – labour shortages have affected service levels and inflation has been rampant. Private hospital operators have responded by launching a campaign against the health insurers and pressuring the government for a bailout. While additional payments or a tax may provide short-term relief to hospitals, they do not solve the structural issues facing the sector and ultimately would drive up the cost of healthcare and premiums for millions of Australians. To build a sustainable private healthcare system, all participants must work together to find efficiencies and drive down the overall cost of care.

Medibank is doing its part to lower costs by investing in new models of care away from overnight stays in expensive acute care hospitals to virtual, short-stay hospitals and home care. Without this transition, Medibank estimates the government will need to spend 50% more on healthcare as a percentage of GDP in 40 years. While this transition does come at the expense of hospitals that typically earn more for longer in-hospital stays, it is beneficial for the wider healthcare system. Higher hospital costs would simply translate to higher premiums, which are likely to push more members out of private health insurance and place further strain on an already stretched public healthcare system.

It is for this reason the Federal Health Minister following a review has conceded, “There’s no silver bullet from Canberra or funding solution from taxpayers to deal with what are essentially private pressures in the system”. Ultimately, it is not the government’s job to prop up unprofitable business models and in some cases, it is healthy for some private hospitals to shut where there is overcapacity in the system.

Has Medibank profited at the expense of hospitals?

Medibank has stuck to its promise not to profit from the pandemic and returned a total of $1.46 billion in givebacks to customers for permanent claims savings due to COVID-19. This is evident in the chart below which shows Medibank’s health insurance gross profit margin is still below FY19 levels.

Figure 1 – Medibank Health Insurance Gross Margin

Source: Company filings

Fear of regulation creates opportunity to invest

While there remains uncertainty as to how the regulatory situation will unfold with a federal election coming up, we think it’s unlikely the government will step in and prop up private hospitals where there is a clear shift to lower-cost care outside the hospital. In the meantime, we believe this creates an opportunity to invest in Australia’s largest health insurer, which has grown its earnings per share at 8% p.a. over the past decade.

Medibank screens as a high-quality business under our investment process for the following reasons:

  1. Financial strength: Medibank has a strong capital position with a capital ratio of 14.1%, well above its 10-12% target range, and has zero debt on its balance sheet.
  2. Business quality: Medibank is Australia’s largest health insurer with 4.2 million members (27% market share). This scale enables Medibank to negotiate better terms with hospitals keeping a lid on claims inflation while sharing these savings with members to lower premiums and improve retention.
  3. Management quality: David Koczkar has been the CEO since 2021 and prior to this was the COO since 2014. Over this period, the company has seen a return to policyholder growth, expanded its health offering and tightly managed its costs.

Finally, from a valuation perspective, Medibank is trading on less than 17x P/E (below its long-term average of 19x) and offers investors an attractive dividend yield of 4.6%.

Figure 2 – Medibank NTM Rolling PE

Source: FactSet

 

Emma Fisher is a Portfolio Manager and Deputy Head of Australian Equities, and Vinay Ranjan is Deputy Portfolio Manager at Magellan-owned, Airlie Funds Management. Magellan Asset Management is a sponsor of Firstlinks. This article has been prepared for general information purposes only and must not be construed as investment advice or as an investment recommendation. This material does not consider your investment objectives, financial situation or particular needs.

For more articles and papers from Magellan, please click here.

 

  •   18 December 2024
  • 7
  •      
  •   

RELATED ARTICLES

Picking the next sector winner

Is ResMed a trap or an opportunity?

Reece Birtles on selecting stocks for income in retirement

banner

Most viewed in recent weeks

Division 296: the initial moves to make before the windows close

What if the best superannuation strategy isn't about earning more, but acting before your options disappear? Several overlooked planning windows are narrowing, with consequences that can last for decades.

The retirement scorecard: how many of these questions can you answer?

From the maths of retirement, estimating spending and picking the right asset allocation to survive a poor decade, here are the questions every retiree – current or future – should be able to answer for themselves.

Testamentary trusts: Treasury has picked the wrong reading

A decades-old estate planning tool has survived one tax crackdown only to be caught by another. The surprise isn't who the reform is targeting, but who could end up paying the price for drafting choices made years ago.

Superannuation’s structural failings

Politicians are fighting over access to super, but they may be arguing about the wrong thing. The system’s three fundamental flaws have been hiding in plain sight for decades, costing Australians far more than they realise.

Avoid unnecessary CGT with this estate planning clause

A simple estate plan can create a ticking time bomb. One overlooked clause can pit spouses against children, delay inheritances, and potentially leave a family facing an unexpected tax bill worth hundreds of thousands of dollars.

Does an American retirement rule work for Australians?

The 4% rule has survived decades of scrutiny, but Australia's retirement system changes the equation in ways most overlook. Before accepting or rejecting this rule of thumb, it pays to understand what really drives retirement outcomes.

Latest Updates

Superannuation

Bill Kelty: Super can't solve everyone's problems

One of the key figures behind Australia’s superannuation system reflects on how it began, what has changed, and why some of today’s biggest debates may be asking too much of a retirement savings system.

Investment strategies

Rising yields have put bonds back in business

For the past decade, investors were forced to chase income wherever they could find it. With yields now offering competition to dividends, the new challenge is deciding whether they're still being adequately rewarded for risk.

Strategy

Do you want a bucket with that?

Retirees, advisers and super funds all talk about the bucket strategy as if it's one thing. It's not. The differences can be significant, and some may matter far more than investors realise when markets become volatile.

Investment strategies

What The Odyssey can teach us about valuation discipline

Investment temptations are hard to resist in the moment, but successful investing is not about ignoring compelling opportunities or ideas. For value investors, the smart move is to prepare before momentum clouds judgement.

Shares

Does market concentration really mean more risk for investors?

One of the most closely watched trends in global markets has become a growing source of investor concern in recent years. Whether that concern is justified, however, turns out to be a far more complicated question.

Retirement

Retirement in reality - 8 months in

Health goals, new friendships and lingering questions about identity have dominated this month. The experience has challenged widely held beliefs about purpose, belonging and what it really means to leave work behind.

Shares

Stagnation might be OK at this point

Australia's economic problems are hardly a secret. The more interesting question for investors is whether the stock market is as exposed to those problems as commonly assumed, or whether the picture is more nuanced.

Sponsors

Alliances

  • ASA-Logo-RGB-ActiveGreen-web.png

© 2026 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.